Our Offerings
By Industry By Function
About Us
Our Viewpoint
NEW
 Senior Management Experts Panel Global Consultants Press Releases Blog
Infographics Market Insights Case Studies Illustrations In The Press
Contact Us
The Business Research Company Logo
Reports Store
Top 50 Healthcare Market Reports
NEW
 Top 50 Non-Healthcare Market Reports
NEW
 Opportunities And Strategies Reports Aerospace And Defense Agriculture Chemicals Construction
Electrical And Electronics Financial Services Food And Beverages Healthcare Services Hospitality Information Technology Machinery Media
Medical Equipment Metal And Mineral Mining Oil And Gas Paper, Plastics, Rubber, Wood And Textile Pharmaceuticals Professional Services Recreation
Retail And Wholesale Services Social Services Transport Transport Services Utilities Veterinary Healthcare Filter Reports by Trends
NEW
Market Intelligence Platform
About GMM Global Forecast
NEW
 Mega Trends Analysis
Consultancies Corporate Planning & Strategy Academic Financial Services Legal Services
Pricing Methodology Sources FAQ Press Coverage
Customized Research
Find Customers Optimise Your Marketing Mix Evaluate Competitors Identify Market Opportunities Develop Products And Services
Distributor And Partner Research Plan Finances Streamline Your Operations Devise Market Entry Strategy Explore Custom Research Packages
NEW
Continuous Research
Desk Research Research Reports Senior Executive Interviews Consumer Research Market Sizing And Forecasts
Company Information Analytics And Data Visualization Research Automation Web Crawling And Spidering AI-Empowered Research Services
Request Proposal
Anti-Vascular Endothelial Growth Factor Therapeutics Global Market Report 2025
Download Free Sample Buy Now
Global Anti-Vascular Endothelial Growth Factor Therapeutics Market Report 2025

Report Price : $4490.00

Pages :

Format : PDF

Published : December 2025

Delivery Time : 2-3 Business Days

Purchase This Report Download Sample PDF
Purchase This Report

Anti-Vascular Endothelial Growth Factor Therapeutics Global Market Report 2025

By Product (Eylea, Lucentis, Beovu), By Disease (Macular Edema, Diabetic Retinopathy, Retinal Vein Occlusion, Age-related Macular Degeneration), By End Users (Hospitals, Clinics, Oncology Centers, Other End Users) – Impact of Tariff and Trade War on Market Size, Growth, Trends, and Forecast 2025–2034

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Anti-Vascular Endothelial Growth Factor Therapeutics Market Overview

• Anti-Vascular Endothelial Growth Factor Therapeutics market size has reached to $12.2 billion in 2024

• Expected to grow to $13.17 billion in 2029 at a compound annual growth rate (CAGR) of 2%

• Growth Driver: Rising Prevalence Of Ophthalmic Diseases Drives Growth In The Anti-VEGF Therapeutics Market

• Market Trend: Advancements In Therapeutics Drive Growth In The Anti-Vegf Therapeutics Market

• North America was the largest region in 2024 and Europe is the fastest growing region.

What Is Covered Under Anti-Vascular Endothelial Growth Factor Therapeutics Market?

Anti-Vascular Endothelial Growth Factor (VEGF) therapeutics are drugs that inhibit the growth of blood vessels, commonly used in the treatment of ophthalmic diseases. These drugs inhibit vascular endothelial growth factors. It is utilized in the therapy of some tumors and in treating age-related macular degeneration.

The main products of anti-vascular endothelial growth factor therapeutics are eylea, Lucentis, and Beovu. Eylea refers to a medication used to treat certain eye conditions, including macular degeneration and diabetic retinopathy. It is used as an anti-vascular endothelial growth factor (anti-VEGF) therapeutic agent to inhibit abnormal blood vessel growth in the eye, often associated with retinal diseases. The anti-vascular endothelial growth factor therapeutics are used for treating macular edema, diabetic retinopathy, retinal vein occlusion, and age-related macular degeneration by hospitals, clinics, oncology centers, and others.

Anti-Vascular Endothelial Growth Factor Therapeutics Market Size and growth rate 2025 to 2029: Graph

What Is The Anti-Vascular Endothelial Growth Factor Therapeutics Market Size 2025 And Growth Rate?

The anti-vascular endothelial growth factor therapeutics market size has grown marginally in recent years. It will grow from$12.2 billion in 2024 to $12.17 billion in 2025 at a compound annual growth rate (CAGR) of 2.0%. The growth in the historic period can be attributed to rise in age-related macular degeneration, increased incidence of diabetic retinopathy, advancements in retinal disease diagnosis, clinical success and efficacy, shift to outpatient treatment

What Is The Anti-Vascular Endothelial Growth Factor Therapeutics Market Growth Forecast?

The anti-vascular endothelial growth factor therapeutics market size is expected to see steady growth in the next few years. It will grow to $13.17 billion in 2029 at a compound annual growth rate (CAGR) of nan%. The growth in the forecast period can be attributed to aging population and ocular diseases, expanding applications in retinal disorders, development of next-generation therapeutics, increasing emphasis on early intervention, global health initiatives and access to treatment. Major trends in the forecast period include increasing utilization in cancer treatment, focus on combination therapies in ophthalmology, exploration of biosimilar versions, research on resistance mechanisms, integration with imaging technologies.

The forecast of 2.0% growth over the next five years reflects a modest reduction of 0.3% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. retinal clinics by inflating prices of vascular endothelial growth factor inhibitors like aflibercept and ranibizumab produced in Ireland and Belgium, resulting in delayed macular degeneration treatment and higher ophthalmology care costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us

What’s The Trade War Impact On Pharmaceuticals Industry?

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

How Is The Anti-Vascular Endothelial Growth Factor Therapeutics Market Segmented?

1) By Product: Eylea, Lucentis, Beovu

2) By Disease: Macular Edema, Diabetic Retinopathy, Retinal Vein Occlusion, Age-related Macular Degeneration

3) By End Users: Hospitals, Clinics, Oncology Centers, Other End Users

Subsegments:

1) By Eylea: Indications, Dosage Forms

2) By Lucentis: Indications, Dosage Forms

3) By Beovu: Indications, Dosage Forms

What Is Driving The Anti-Vascular Endothelial Growth Factor Therapeutics Market? Rising Prevalence Of Ophthalmic Diseases Drives Growth In The Anti-VEGF Therapeutics Market

The increase in the prevalence of ophthalmic diseases is expected to propel the growth of the anti-vascular endothelial growth factor therapeutics market going forward. The prevalence of ophthalmic diseases refers to the number or proportion of individuals within a given population who have been diagnosed with or exhibit specific eye conditions or diseases. Anti-vascular endothelial growth factor (VEGF) therapeutics help reduce the prevalence of ophthalmic diseases by effectively treating ailments such as wet age-related macular degeneration (AMD), diabetic retinopathy, and retinal vein occlusion. For instance, in October 2022, according to World Health Organization, a Switzerland-based international public health organization, globally, around 2.2 billion people have near or distance vision impairment, and 1 billion people suffer from near or distance vision impairment. Further, among these, 88.4 million are suffering from refractive error, 94 million have cataracts, 8 million have age-related macular degeneration, and around 3.9 million have diabetic retinopathy. Therefore, the increase in the prevalence of ophthalmic diseases is driving the growth of the anti-vascular endothelial growth factor therapeutics industry.

What Is Driving The Anti-Vascular Endothelial Growth Factor Therapeutics Market? Increasing Healthcare Infrastructure Expenditure Boosts Growth In The Anti-VEGF Therapeutics Market

Growing expenditure on healthcare infrastructure is expected to propel the growth of the anti-vascular endothelial growth factor therapeutics market going forward. Healthcare infrastructure expenditure refers to the financial resources allocated to the development, maintenance, and improvement of healthcare facilities and related assets, such as hospitals, clinics, medical equipment, and information systems. Healthcare infrastructure expenditure plays a crucial role in the anti-VEGF therapeutics market by improving access to treatment, supporting the adoption of new technologies, increasing awareness and early detection, and fostering public-private collaboration in research and development. For instance, in May 2024, according to a report published by the Office for National Statistics, a UK-based government department, total healthcare expenditure rose by 5.6% in nominal terms from 2022 to 2023, in contrast to growth of just 0.9% in 2022. Therefore, growing expenditure on healthcare infrastructure is driving the growth of the anti-vascular endothelial growth factor therapeutics industry.

Who Are The Major Players In The Global Anti-Vascular Endothelial Growth Factor Therapeutics Market?

Major companies operating in the anti-vascular endothelial growth factor therapeutics market include F. Hoffmann-La Roche AG, Biogen Inc., Pfizer Inc., Coherus BioSciences Inc., Eli Lilly and Company, Bausch Health Companies Inc., Viatris Inc., Xbrane Biopharma AB, Bayer AG, Regeneron Pharmaceuticals Inc., Genentech Inc, Allergan Inc., Novartis AG, kyowa Kirin Co. Ltd., Amgen Inc., AstraZeneca plc, Merck & Co. Inc., Johnson & Johnson Private Limited, Sanofi S.A., AbbVie Inc., Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., Bristol-Myers Squibb Company, Boehringer Ingelheim International GmbH, Daiichi Sankyo Company Limited, Eisai Co. Ltd., Gilead Sciences Inc., Vertex Pharmaceuticals Incorporated, Alexion Pharmaceuticals Inc.

What Are The Key Trends Of The Global Anti-Vascular Endothelial Growth Factor Therapeutics Market? Advancements In Therapeutics Drive Growth In The Anti-Vegf Therapeutics Market

Advancements in therapeutics are a key trend gaining popularity in the anti-vascular endothelial growth factor therapeutics market. Companies operating in the anti-vascular endothelial growth factor therapeutics market are adopting advanced therapeutics to sustain their position in the market. For instance, in May 2022, Ashvattha Therapeutics Inc., a US-based clinical-stage biopharmaceutical company, released phase 1 safety data for healthy subjects for subcutaneous anti-VEGF wet AMD (age-related macular degeneration) and DME (diabetic macular edema) candidates. D-4517.2 therapy is a first-in-class therapy developed to address the unmet needs of DME conditions. D-4517.2 therapy is being developed for self-administration using an autoinjector. The autoinjector D-4517.2 enable patients to self-administer the medication once a month in the comfort of their home.

What Are The Key Trends Of The Global Anti-Vascular Endothelial Growth Factor Therapeutics Market? Strategic Partnerships Drive Commercialization Efforts In The Anti-Vegf Therapeutics Market

Major companies operating in the anti-vascular endothelial growth factor therapeutics market are integrating their efforts in adopting strategic partnerships to develop and commercialize VEGF inhibitors and maximize their profits in the market. Such collaborations are essential for driving research and development, accessing new technologies and candidates, expanding market reach, and supporting the commercialization of VEGF inhibitors. For instance, in June 2022, Biogen Inc., a US-based biotechnology company, in partnership with Samsung Bioepis, a South Korea-based biopharmaceutical company, launched BYOOVIZ (ranibizumab-nuna) in the United States. BYOOVIZ, the first FDA-approved ophthalmology biosimilar, is indicated for the treatment of neovascular (wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion, and myopic choroidal neovascularization. It is a vascular endothelial growth factor (VEGF) inhibitor and the first biosimilar launch in the U.S. under the Biogen and Samsung Bioepis’ partnership, where Samsung Bioepis is responsible for the development, regulatory registration, and manufacture of the products, while Biogen is responsible for commercialization.

Need data on a specific region in this market?
Request Regional Data

Anti-Vascular Endothelial Growth Factor Therapeutics Market Merger And Acquisition: Bristol Myers Squibb Acquires Turning Point Therapeutics to Enhance Oncology Portfolio

In August 2022, Coherus BioSciences Inc., a US-based commercial-stage biopharmaceutical company, acquired the commercialization rights to FYB203 from Klinge Biopharma GmbH for an undisclosed amount. This acquisition enhances Coherus's portfolio of ophthalmology products, particularly in the anti-VEGF (vascular endothelial growth factor) segment. Klinge Biopharma GmbH is a Germany-based pharmaceutical manufacturing company.

Regional Analysis For The Global Anti-Vascular Endothelial Growth Factor Therapeutics Market

North America was the largest region in the anti-vascular endothelial growth factor therapeutics market in 2024.Europe is expected to be the fastest-growing region in the global anti-vascular endothelial growth factor therapeutics market report during the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Anti-Vascular Endothelial Growth Factor Therapeutics Market?

The anti-vascular endothelial growth factor therapeutics market consists of revenues earned by entities by providing lapatinib (tykerb), sorafenib (nexavar), sunitinib (sutent), axitinib, and pazopanib. The market value includes the value of related goods sold by the service provider or included within the service offering. The anti-vascular endothelial growth factor therapeutics market also includes sales of drugs, injectables, and therapy-related products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Anti-Vascular Endothelial Growth Factor Therapeutics Industry?

The anti-vascular endothelial growth factor therapeutics market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the anti-vascular endothelial growth factor therapeutics industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

Anti-Vascular Endothelial Growth Factor Therapeutics Market Report Forecast Analysis

Report AttributeDetails
Market Size Value In 2025 $12.17 billion
Revenue Forecast In 2034 $13.17 billion
Growth Rate CAGR of % from 2025 to 2034
Base Year For Estimation 2024
Actual Estimates/Historical Data 2019-2024
Forecast Period 2025 - 2029 - 2034
Market Representation Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered 1) By Product: Eylea, Lucentis, Beovu
2) By Disease: Macular Edema, Diabetic Retinopathy, Retinal Vein Occlusion, Age-related Macular Degeneration
3) By End Users: Hospitals, Clinics, Oncology Centers, Other End Users Subsegments: 1) By Eylea: Indications, Dosage Forms
2) By Lucentis: Indications, Dosage Forms
3) By Beovu: Indications, Dosage Forms
Regional Scope Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled F. Hoffmann-La Roche AG, Biogen Inc., Pfizer Inc., Coherus BioSciences Inc., Eli Lilly and Company, Bausch Health Companies Inc., Viatris Inc., Xbrane Biopharma AB, Bayer AG, Regeneron Pharmaceuticals Inc., Genentech Inc, Allergan Inc., Novartis AG, kyowa Kirin Co. Ltd., Amgen Inc., AstraZeneca plc, Merck & Co. Inc., Johnson & Johnson Private Limited, Sanofi S.A., AbbVie Inc., Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., Bristol-Myers Squibb Company, Boehringer Ingelheim International GmbH, Daiichi Sankyo Company Limited, Eisai Co. Ltd., Gilead Sciences Inc., Vertex Pharmaceuticals Incorporated, Alexion Pharmaceuticals Inc.
Customization ScopeRequest for Sample
Pricing And Purchase OptionsExplore Purchase Options

Table Of Contents

1. Executive Summary

2. Anti-Vascular Endothelial Growth Factor Therapeutics Market Characteristics

3. Anti-Vascular Endothelial Growth Factor Therapeutics Market Trends And Strategies

4. Anti-Vascular Endothelial Growth Factor Therapeutics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Anti-Vascular Endothelial Growth Factor Therapeutics Growth Analysis And Strategic Analysis Framework

5.1. Global Anti-Vascular Endothelial Growth Factor Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

5.2. Analysis Of End Use Industries

5.3. Global Anti-Vascular Endothelial Growth Factor Therapeutics Market Growth Rate Analysis

5.4. Global Anti-Vascular Endothelial Growth Factor Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

5.5. Global Anti-Vascular Endothelial Growth Factor Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

5.6. Global Anti-Vascular Endothelial Growth Factor Therapeutics Total Addressable Market (TAM)

6. Anti-Vascular Endothelial Growth Factor Therapeutics Market Segmentation

6.1. Global Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Eylea

Lucentis

Beovu

6.2. Global Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Macular Edema

Diabetic Retinopathy

Retinal Vein Occlusion

Age-related Macular Degeneration

6.3. Global Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hospitals

Clinics

Oncology Centers

Other End Users

6.4. Global Anti-Vascular Endothelial Growth Factor Therapeutics Market, Sub-Segmentation Of Eylea, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Indications

Dosage Forms

6.5. Global Anti-Vascular Endothelial Growth Factor Therapeutics Market, Sub-Segmentation Of Lucentis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Indications

Dosage Forms

6.6. Global Anti-Vascular Endothelial Growth Factor Therapeutics Market, Sub-Segmentation Of Beovu, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Indications

Dosage Forms

7. Anti-Vascular Endothelial Growth Factor Therapeutics Market Regional And Country Analysis

7.1. Global Anti-Vascular Endothelial Growth Factor Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

7.2. Global Anti-Vascular Endothelial Growth Factor Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Anti-Vascular Endothelial Growth Factor Therapeutics Market

8.1. Asia-Pacific Anti-Vascular Endothelial Growth Factor Therapeutics Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

8.2. Asia-Pacific Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.3. Asia-Pacific Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.4. Asia-Pacific Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Anti-Vascular Endothelial Growth Factor Therapeutics Market

9.1. China Anti-Vascular Endothelial Growth Factor Therapeutics Market Overview

9.2. China Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.3. China Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.4. China Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Anti-Vascular Endothelial Growth Factor Therapeutics Market

10.1. India Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.2. India Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.3. India Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Anti-Vascular Endothelial Growth Factor Therapeutics Market

11.1. Japan Anti-Vascular Endothelial Growth Factor Therapeutics Market Overview

11.2. Japan Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.3. Japan Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.4. Japan Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Anti-Vascular Endothelial Growth Factor Therapeutics Market

12.1. Australia Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.2. Australia Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.3. Australia Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Anti-Vascular Endothelial Growth Factor Therapeutics Market

13.1. Indonesia Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.2. Indonesia Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.3. Indonesia Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Anti-Vascular Endothelial Growth Factor Therapeutics Market

14.1. South Korea Anti-Vascular Endothelial Growth Factor Therapeutics Market Overview

14.2. South Korea Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.3. South Korea Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.4. South Korea Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Anti-Vascular Endothelial Growth Factor Therapeutics Market

15.1. Western Europe Anti-Vascular Endothelial Growth Factor Therapeutics Market Overview

15.2. Western Europe Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.3. Western Europe Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.4. Western Europe Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Anti-Vascular Endothelial Growth Factor Therapeutics Market

16.1. UK Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.2. UK Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.3. UK Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Anti-Vascular Endothelial Growth Factor Therapeutics Market

17.1. Germany Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.2. Germany Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.3. Germany Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Anti-Vascular Endothelial Growth Factor Therapeutics Market

18.1. France Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.2. France Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.3. France Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Anti-Vascular Endothelial Growth Factor Therapeutics Market

19.1. Italy Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.2. Italy Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.3. Italy Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Anti-Vascular Endothelial Growth Factor Therapeutics Market

20.1. Spain Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.2. Spain Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.3. Spain Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Anti-Vascular Endothelial Growth Factor Therapeutics Market

21.1. Eastern Europe Anti-Vascular Endothelial Growth Factor Therapeutics Market Overview

21.2. Eastern Europe Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.3. Eastern Europe Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.4. Eastern Europe Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Anti-Vascular Endothelial Growth Factor Therapeutics Market

22.1. Russia Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.2. Russia Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.3. Russia Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Anti-Vascular Endothelial Growth Factor Therapeutics Market

23.1. North America Anti-Vascular Endothelial Growth Factor Therapeutics Market Overview

23.2. North America Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.3. North America Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.4. North America Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Anti-Vascular Endothelial Growth Factor Therapeutics Market

24.1. USA Anti-Vascular Endothelial Growth Factor Therapeutics Market Overview

24.2. USA Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.3. USA Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.4. USA Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Anti-Vascular Endothelial Growth Factor Therapeutics Market

25.1. Canada Anti-Vascular Endothelial Growth Factor Therapeutics Market Overview

25.2. Canada Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.3. Canada Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.4. Canada Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Anti-Vascular Endothelial Growth Factor Therapeutics Market

26.1. South America Anti-Vascular Endothelial Growth Factor Therapeutics Market Overview

26.2. South America Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.3. South America Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.4. South America Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Anti-Vascular Endothelial Growth Factor Therapeutics Market

27.1. Brazil Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.2. Brazil Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.3. Brazil Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Anti-Vascular Endothelial Growth Factor Therapeutics Market

28.1. Middle East Anti-Vascular Endothelial Growth Factor Therapeutics Market Overview

28.2. Middle East Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.3. Middle East Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.4. Middle East Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Anti-Vascular Endothelial Growth Factor Therapeutics Market

29.1. Africa Anti-Vascular Endothelial Growth Factor Therapeutics Market Overview

29.2. Africa Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.3. Africa Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.4. Africa Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Anti-Vascular Endothelial Growth Factor Therapeutics Market Competitive Landscape And Company Profiles

30.1. Anti-Vascular Endothelial Growth Factor Therapeutics Market Competitive Landscape

30.2. Anti-Vascular Endothelial Growth Factor Therapeutics Market Company Profiles

30.2.1. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis

30.2.2. Biogen Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.3. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.4. Coherus BioSciences Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.5. Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis

31. Anti-Vascular Endothelial Growth Factor Therapeutics Market Other Major And Innovative Companies

31.1. Bausch Health Companies Inc.

31.2. Viatris Inc.

31.3. Xbrane Biopharma AB

31.4. Bayer AG

31.5. Regeneron Pharmaceuticals Inc.

31.6. Genentech Inc

31.7. Allergan Inc.

31.8. Novartis AG

31.9. kyowa Kirin Co. Ltd.

31.10. Amgen Inc.

31.11. AstraZeneca plc

31.12. Merck & Co. Inc.

31.13. Johnson & Johnson Private Limited

31.14. Sanofi S.A.

31.15. AbbVie Inc.

32. Global Anti-Vascular Endothelial Growth Factor Therapeutics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Anti-Vascular Endothelial Growth Factor Therapeutics Market

34. Recent Developments In The Anti-Vascular Endothelial Growth Factor Therapeutics Market

35. Anti-Vascular Endothelial Growth Factor Therapeutics Market High Potential Countries, Segments and Strategies

35.1 Anti-Vascular Endothelial Growth Factor Therapeutics Market In 2029 - Countries Offering Most New Opportunities

35.2 Anti-Vascular Endothelial Growth Factor Therapeutics Market In 2029 - Segments Offering Most New Opportunities

35.3 Anti-Vascular Endothelial Growth Factor Therapeutics Market In 2029 - Growth Strategies

35.3.1 Market Trend Based Strategies

35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations

36.2. Currencies

36.3. Historic And Forecast Inflation Rates

36.4. Research Inquiries

36.5. The Business Research Company

36.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Table 3: Global Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 4: Global Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 5: Global Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 6: Global Anti-Vascular Endothelial Growth Factor Therapeutics Market, Sub-Segmentation Of Eylea, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 7: Global Anti-Vascular Endothelial Growth Factor Therapeutics Market, Sub-Segmentation Of Lucentis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 8: Global Anti-Vascular Endothelial Growth Factor Therapeutics Market, Sub-Segmentation Of Beovu, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 9: Global Anti-Vascular Endothelial Growth Factor Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 10: Global Anti-Vascular Endothelial Growth Factor Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 11: Asia-Pacific, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 12: Asia-Pacific, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 13: Asia-Pacific, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 14: China, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 15: China, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 16: China, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 17: India, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 18: India, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 19: India, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 20: Japan, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 21: Japan, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 22: Japan, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 23: Australia, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 24: Australia, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 25: Australia, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 26: Indonesia, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 27: Indonesia, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 28: Indonesia, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 29: South Korea, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 30: South Korea, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 31: South Korea, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 32: Western Europe, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 33: Western Europe, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 34: Western Europe, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 35: UK, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 36: UK, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 37: UK, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 38: Germany, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 39: Germany, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 40: Germany, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 41: France, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 42: France, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 43: France, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 44: Italy, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 45: Italy, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 46: Italy, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 47: Spain, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 48: Spain, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 49: Spain, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 50: Eastern Europe, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 51: Eastern Europe, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 52: Eastern Europe, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 53: Russia, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 54: Russia, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 55: Russia, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 56: North America, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 57: North America, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 58: North America, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 59: USA, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 60: USA, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 61: USA, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 62: Canada, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 63: Canada, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 64: Canada, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 65: South America, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 66: South America, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 67: South America, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 68: Brazil, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 69: Brazil, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 70: Brazil, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 71: Middle East, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 72: Middle East, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 73: Middle East, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 74: Africa, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 75: Africa, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 76: Africa, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 77: F. Hoffmann-La Roche AG Financial Performance
  • Table 78: Biogen Inc. Financial Performance
  • Table 79: Pfizer Inc. Financial Performance
  • Table 80: Coherus BioSciences Inc. Financial Performance
  • Table 81: Eli Lilly and Company Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Figure 3: Global Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 4: Global Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 5: Global Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 6: Global Anti-Vascular Endothelial Growth Factor Therapeutics Market, Sub-Segmentation Of Eylea, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 7: Global Anti-Vascular Endothelial Growth Factor Therapeutics Market, Sub-Segmentation Of Lucentis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 8: Global Anti-Vascular Endothelial Growth Factor Therapeutics Market, Sub-Segmentation Of Beovu, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 9: Global Anti-Vascular Endothelial Growth Factor Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 10: Global Anti-Vascular Endothelial Growth Factor Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 11: Asia-Pacific, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 12: Asia-Pacific, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 13: Asia-Pacific, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 14: China, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 15: China, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 16: China, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 17: India, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 18: India, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 19: India, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 20: Japan, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 21: Japan, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 22: Japan, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 23: Australia, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 24: Australia, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 25: Australia, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 26: Indonesia, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 27: Indonesia, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 28: Indonesia, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 29: South Korea, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 30: South Korea, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 31: South Korea, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 32: Western Europe, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 33: Western Europe, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 34: Western Europe, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 35: UK, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 36: UK, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 37: UK, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 38: Germany, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 39: Germany, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 40: Germany, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 41: France, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 42: France, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 43: France, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 44: Italy, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 45: Italy, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 46: Italy, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 47: Spain, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 48: Spain, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 49: Spain, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 50: Eastern Europe, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 51: Eastern Europe, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 52: Eastern Europe, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 53: Russia, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 54: Russia, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 55: Russia, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 56: North America, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 57: North America, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 58: North America, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 59: USA, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 60: USA, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 61: USA, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 62: Canada, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 63: Canada, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 64: Canada, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 65: South America, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 66: South America, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 67: South America, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 68: Brazil, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 69: Brazil, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 70: Brazil, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 71: Middle East, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 72: Middle East, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 73: Middle East, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 74: Africa, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 75: Africa, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 76: Africa, Anti-Vascular Endothelial Growth Factor Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 77: F. Hoffmann-La Roche AG Financial Performance
  • Figure 78: Biogen Inc. Financial Performance
  • Figure 79: Pfizer Inc. Financial Performance
  • Figure 80: Coherus BioSciences Inc. Financial Performance
  • Figure 81: Eli Lilly and Company Financial Performance

Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market Forecast 2025–2034: Trends Reshaping Demand, Investment, and Innovation

Read More About Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market Forecast 2025–2034: Trends Reshaping Demand, Investment, and Innovation

Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Projected to Reach $47.74 Billion by 2029 at a CAGR of 30.7%

Read More About Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Projected to Reach $47.74 Billion by 2029 at a CAGR of 30.7%

$8.21 Billion Forecast for Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market by 2029, Backed by Demand and Innovation

Read More About $8.21 Billion Forecast for Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market by 2029, Backed by Demand and Innovation

Fentanyl Market Forecast Reaching $22.03 Billion by 2029 at 6.5% CAGR

Read More About Fentanyl Market Forecast Reaching $22.03 Billion by 2029 at 6.5% CAGR

A 2025 analysis offering size estimates, growth trends and technological innovations in the live cell imaging microscopes market.

Read More About A 2025 analysis offering size estimates, growth trends and technological innovations in the live cell imaging microscopes market.

A 2025 market overview covering growth forecasts, treatment landscape, and key stakeholders in the isovaleric acidemia treatment market.

Read More About A 2025 market overview covering growth forecasts, treatment landscape, and key stakeholders in the isovaleric acidemia treatment market.

Discover key trends and market dynamics in the Mycobacterium Tuberculosis Market with 2025 insights from The Business Research Company.

Read More About Discover key trends and market dynamics in the Mycobacterium Tuberculosis Market with 2025 insights from The Business Research Company.

Discover key trends and market dynamics in the Smoking Cessation & Nicotine De-addiction Products Market with 2025 insights from The Business Research Company.

Read More About Discover key trends and market dynamics in the Smoking Cessation & Nicotine De-addiction Products Market with 2025 insights from The Business Research Company.

Anti-Vascular Endothelial Growth Factor Therapeutics Global Market Report 2025 – By Product (Eylea, Lucentis, Beovu), By Disease (Macular Edema, Diabetic Retinopathy, Retinal Vein Occlusion, Age-related Macular Degenerat...

View Report

Tumor Necrosis Factor Inhibitor Drugs Global Market Report 2025 – By Product Type (Humira, Enbrel, Remicade, Simponi/Simponi Aria, Cimzia, Biosimilars ), By Route Of Administration (Subcutaneous Injection, Intravenous In...

View Report

Angina Pectoris Drugs Global Market Report 2025 – By Drugs (Nitrates, Antiplatelet Agents, Beta-adrenergic Blocking Agents, Calcium Channel Blockers, Anti-ischemic Agents, Statins, Antihypertensive Agents, Other Drugs), ...

View Report

Rheumatology Therapeutics Global Market Report 2025 – By Drug Class (Disease Modifying Anti-Rheumatic Drugs, Nonsteroidal Anti-Inflammatory Drugs, Corticosteroids, Uric Acid Drugs, Other Drugs Classes), By Distribution C...

View Report

Atherosclerosis Drugs Global Market Report 2025 – By Drug Class (Anti-Platelet Medications, Fibric Acid And Omega-3 Fatty Acid Derivatives, Angiotensin-Covering Enzyme (ACE) Inhibitors, Diuretics, Cholesterol Lowering Me...

View Report

Vascular Stent Global Market Report 2025 – By Product( Coronary Stents, Peripheral Vascular Stents, Ever Stent Grafts), By Type( Bare Metal Stent, Bio-engineered Stent, Bioresorbable Vascular Scaffold, Drug Eluting Stent...

View Report

Urothelial Cancer Drugs Global Market Report 2025 – By Type( Urothelial Carcinoma, Squamous Cell Carcinoma, Adenocarcinoma), By Treatment( Immunotherapy, Chemotherapy, Preservation Therapy), By Distribution Channel( Hosp...

View Report

Anti-Inflammatory Therapeutics Global Market Report 2025 – By Drug Class (Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Corticosteroids, Anti-Inflammatory Biologics), By Indication (Arthritis, Respiratory Diseases, Mult...

View Report

Frequently Asked Questions

Anti-Vascular Endothelial Growth Factor (VEGF) therapeutics are drugs that inhibit the growth of blood vessels, commonly used in the treatment of ophthalmic diseases. These drugs inhibit vascular endothelial growth factors. It is utilized in the therapy of some tumors and in treating age-related macular degeneration. For further insights on this market, request a sample here

The market major growth driver - Rising Prevalence Of Ophthalmic Diseases Drives Growth In The Anti-VEGF Therapeutics Market. For further insights on this market, request a sample here

The anti-vascular endothelial growth factor therapeutics market size has declined marginally in recent years. It will grow from " $12.2 billion in 2024 to $12.17 billion in 2025 at a compound annual growth rate (CAGR) of -0.2%. The growth in the historic period can be attributed to rise in age-related macular degeneration, increased incidence of diabetic retinopathy, advancements in retinal disease diagnosis, clinical success and efficacy, shift to outpatient treatment The anti-vascular endothelial growth factor therapeutics market size is expected to see marginal growth in the next few years. It will grow to " $13.17 billion in 2029 at a compound annual growth rate (CAGR) of 2.0%. The growth in the forecast period can be attributed to aging population and ocular diseases, expanding applications in retinal disorders, development of next-generation therapeutics, increasing emphasis on early intervention, global health initiatives and access to treatment. Major trends in the forecast period include increasing utilization in cancer treatment, focus on combination therapies in ophthalmology, exploration of biosimilar versions, research on resistance mechanisms, integration with imaging technologies. For further insights on this market, request a sample here

The anti-vascular endothelial growth factor therapeutics market covered in this report is segmented –
1) By Product: Eylea, Lucentis, Beovu
2) By Disease: Macular Edema, Diabetic Retinopathy, Retinal Vein Occlusion, Age-related Macular Degeneration
3) By End Users: Hospitals, Clinics, Oncology Centers, Other End Users Subsegments:
1) By Eylea: Indications, Dosage Forms
2) By Lucentis: Indications, Dosage Forms
3) By Beovu: Indications, Dosage Forms For further insights on this market, request a sample here

North America was the largest region in the anti-vascular endothelial growth factor therapeutics market in 2024.Europe is expected to be the fastest-growing region in the global anti-vascular endothelial growth factor therapeutics market report during the forecast period. The regions covered in the anti-vascular endothelial growth factor therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa For further insights on this market, request a sample here.

Major companies operating in the anti-vascular endothelial growth factor therapeutics market include F. Hoffmann-La Roche AG, Biogen Inc., Pfizer Inc., Coherus BioSciences Inc., Eli Lilly and Company, Bausch Health Companies Inc., Viatris Inc., Xbrane Biopharma AB, Bayer AG, Regeneron Pharmaceuticals Inc., Genentech Inc, Allergan Inc., Novartis AG, kyowa Kirin Co. Ltd., Amgen Inc., AstraZeneca plc, Merck & Co. Inc., Johnson & Johnson Private Limited, Sanofi S.A., AbbVie Inc., Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., Bristol-Myers Squibb Company, Boehringer Ingelheim International GmbH, Daiichi Sankyo Company Limited, Eisai Co. Ltd., Gilead Sciences Inc., Vertex Pharmaceuticals Incorporated, Alexion Pharmaceuticals Inc. . For further insights on this market, request a sample here.

Major trends in this market include Advancements In Therapeutics Drive Growth In The Anti-Vegf Therapeutics Market. For further insights on this market, request a sample here.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us
Global Anti-Vascular Endothelial Growth Factor Therapeutics Market Report 2025

Wait, we have a special offer for you! ✋

Get your exclusive 20% discount only on the Global Market Reports now using the code ONLINE20*

YES, get the discount! No, I'd pay the full price

*Copy paste the discount code in the cart

Back to top WhatsApp icon